Table 3.
Effects of CPhGs on the serum HA, LN, PCIII, IV-C activities of hepatic fibrosis rats
| Group | Dose (mg/kg/day) | n | HA (mg/l) | LN (mg/l) | PCIII (mg/l) | IV-C (mg/l) |
|---|---|---|---|---|---|---|
| Normal | — | 12 | 98.67 ± 15.798** | 21.27 ± 3.003** | 12.69 ± 6.525** | 1.99 ± 0.691** |
| Model | — | 11 | 116.08 ± 7.683 | 29.38 ± 4.716 | 33.87 ± 16.336 | 8.10 ± 0.369 |
| BJRG | 600 | 10 | 106.85 ± 7.650** | 23.35 ± 3.106* | 21.09 ± 7.113 | 2.16 ± 0.603** |
| CPhGs | 500 | 12 | 104.97 ± 9.139** | 23.91 ± 5.945* | 23.58 ± 8.815 | 2.52 ± 0.464** |
| 250 | 9 | 106.19 ± 6.250** | 24.12 ± 3.593* | 24.07 ± 11.859 | 3.10 ± 0.692** | |
| 125 | 10 | 108.11 ± 8.261* | 25.41 ± 4.925 | 21.79 ± 7.877 | 3.39 ± 0.980** |
Values are expressed as mean ± SD, n = Survival number of animals
* P < 0.05, Compared with the model group; ** P < 0.01, Compared with the model group